Coronavirus. Credit: European Centers for Disease Control

Moscow announced on Saturday that it had registered its third vaccine against the coronavirus and promised to introduce the shock to the Russian population by March.

Russia was the first country to register a vaccine for COVID-19 prior to clinical trials in August, and the Sputnik V stab has been approved in more than two dozen countries around the world.

“Today we note that a third vaccine, CoviVac, has been registered,” Prime Minister Mikhail Mishustin said at a government meeting on state television.

“And the first 120,000 cans will be distributed in civilian traffic as early as mid-March,” he told the cabinet.

First received with skepticism, the effectiveness of Sputnik V was confirmed by The Lancet Medical Journal earlier this month.

Moscow relied on the nationwide rollout of the vaccine to stave off the effects of a second wave of infections that struck the country late last year.

However, recently released mortality data showed that the death rate in Russia was still one of the highest in the world.

President Vladimir Putin announced in October that the country had registered its second vaccine, EpiVacCorona, which health officials said it would go into mass production this month.

Mishustin said Saturday that Russia made 10 million doses of Sputnik and 80,000 batches of the EpiVacCorona vaccine developed by the Siberian vector laboratory.

With the introduction of the third trick on Saturday, the Prime Minister said: “Today Russia is the only country that already has three vaccines to prevent COVID infections.”

CoviVac was made by the Chumakov State Center in Moscow, which used a different development method than Sputnik and EpiVacCorona using an inactive virus.

The vaccine is expected to complete the final clinical phase with 3,000 participants in March and has so far been recommended for people under 60 years of age.

Follow the latest news on the Coronavirus (COVID-19) outbreak

© 2021 AFP

Quote: Russia says registers third coronavirus vaccine (2021, February 20), accessed from on February 20, 2021

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.


Please enter your comment!
Please enter your name here